|
Bioniche Presents Additional Data on the Anticancer Activity of MCC Against Peritoneal Carcinomatosis |
|
|
|
17 Apr 2007 |
Bioniche Life Sciences Inc. (TSX:BNC), a research-based technology driven Canadian Biopharmaceutical company, presented data yesterday showing that intraperitoneal administration of the Company's proprietary Mycobacterial Cell Wall-DNA Complex (MCC) results in significant anticancer activity against both micrometastases and macrometastases present in the peritoneal cavity of rats with colon cancer peritoneal carcinomatosis.
BELLEVILLE, Canada | April 16, 2007 | Bioniche Life Sciences Inc. (TSX:BNC), a research-based technology driven Canadian Biopharmaceutical company, presented data yesterday showing that intraperitoneal administration of the Company's proprietary Mycobacterial Cell Wall-DNA Complex (MCC) results in significant anticancer activity against both micrometastases and macrometastases present in the peritoneal cavity of rats with colon cancer peritoneal carcinomatosis. The data was presented at the American Association for Cancer Research (AACR) Annual Meeting 2007, being held from April 14-18 in Los Angeles, California, USA.
The study was co-authored by Mario C. Filion, Benoit Filion and Nigel C. Phillips of Bioniche Life Sciences Inc., Montréal, Québec, Canada and by Caroline Mignard, Olivier Raguin and Francis Bichat of Oncodesign Biotechnology, Dijon, France. The study evaluated the in vivo anticancer activity of MCC against microscopic and macroscopic peritoneal nodes after administration of rat PROb colon cancer cells in animals.
"MCC suspension demonstrates significant dose-related anticancer activity in rats having experimental colon microscopic (micrometastases) and macroscopic (macrometastases) nodes in the peritoneum," said Nigel C. Phillips, Senior Vice-President of Scientific Affairs and Chief Scientific Officer at Bioniche Life Sciences Inc. "These additional data confirm the potential application of MCC for treatment of patients with peritoneal metastasis from colorectal cancer."
"This is of particular interest given that treatment options for managements of metastases presented in the peritoneal cavity (peritoneal carcinomatosis) are currently very limited," added Dr. Phillips.
"Bioniche is currently conducting its Phase III clinical program using MCC (trademarked Urocidin) for the treatment of non muscle-invasive bladder cancer," added Graeme McRae, President & CEO of Bioniche Life Sciences Inc. "The first of two Phase III clinical trials began last November in a patient population that is refractory (unresponsive) to the current standard therapy, an area of unmet need. The Company is anxious to proceed with a Phase I/II clinical trial in intraperitoneal uses of MCC, specifically in the treatment of ovarian and colorectal cancers, for which there are limited treatment options available."
About the Mycobacterial Cell Wall Technology Platform
Bioniche's core mycobacterial cell wall technology platform comprises a number of different compositions with a spectrum of activity that comprises antiviral, antibacterial, immune stimulatory and immune adjuvant, as well as anticancer and chemotherapeutic activity against cancer cells. A number of compositions are commercialized for use in veterinary applications, and the Company is actively developing compositions for use in a number of human applications.
SOURCE: Bioniche Life Sciences Inc. |
